hcplive podcasts

Peer Exchange

EP. 1: C. Difficile Risk Factors and Manifestation

EP. 2: Strains of C. Difficile

EP. 3: Managing Community-Onset C. Difficile

EP. 4: Recurrent C. Difficile

EP. 5: C. Difficile: A Differential Diagnosis

EP. 6: Testing for C. Difficile Infections

EP. 7: Screening for C. Difficile

EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options

EP. 9: C. Difficile: Updates to Clinical Practice Guidelines

EP. 10: Selecting Therapy to Treat C. Difficile

EP. 11: C. Difficile Treatment: Fidaxomicin

EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections

EP. 13: C. Difficile Treatment: Bezlotoxumab

EP. 14: Preventing/Treating C. Difficile: Unmet Needs

EP. 15: Fecal Microbiota Transplantation for C. Difficile Infections

EP. 16: Emerging Treatment Options for C. Difficile Infections

EP. 17: C. Difficile: Barriers Treating With FMT

EP. 18: Making Strides in the Management of C. Difficile

EP. 1: Burden of HIV in the USA and Associated Symptoms

EP. 2: Screening Recommendations for HIV and Risk Stratification

EP. 3: PrEP Therapy for High-Risk HIV Candidates

EP. 4: Safety Profiles of FDA-Approved PrEP Agents

EP. 5: State Medicaid Reimbursement for Routine HIV Screening

EP. 6: Rapid Initiation of HIV Treatment With ART

EP. 7: Factors Considered in Choosing Initial HIV Therapeutic Regimen

EP. 8: Safety Profile and Costs of Initial HIV Therapeutic Regimen

EP. 9: Switching Therapies in Patients Who Are Successfully Treated

EP. 10: Virological Failure or Rebound to HIV Therapies

EP. 11: Emerging Treatment Options for HIV

EP. 12: Drug Resistance or Intolerance to HIV Therapy

EP. 13: Long-Acting Injectables to Treat HIV

EP. 14: Long-Acting Injectables as PrEP Therapy

EP. 1: The HIV Treatment Landscape

EP. 2: HIV Screening and Diagnosis

EP. 3: HIV Pre-Exposure Prophylaxis Therapy

EP. 4: HIV Treatment: Initiation, Adherence, and Accessibility

EP. 5: HIV US Preventive Task Force Screening Recommendations

EP. 6: HIV: Undetectable Equals Untransmittable

EP. 7: HIV Therapy Selection for the General Population

EP. 8: HHS vs IAS-USA Guidelines for HIV

EP. 9: HIV Treatment Options for Pregnant Women

EP. 10: Dolutegravir + Rilpivirine Combination Therapy for HIV

EP. 11: The Difficulty of Switching ART Regimens in HIV

EP. 12: Recommended HIV-Monitoring Approach for Stable Patients

EP. 13: Virological Failure and Incomplete Response in HIV

EP. 14: Significance of Low-Level Viremia Indication in HIV

EP. 15: HIV Long-Acting Injectable Therapies in Development

EP. 16: HIV Noninjectable Long-Acting Therapies in Development

EP. 1: An Overview of ABSSSI

EP. 2: Understanding the Prevalence of ABSSSI in the Community

EP. 3: ABSSSI: Standard Protocol of Admission and Treatment

EP. 4: Cost Considerations of IV Antibiotics for ABSSSI

EP. 5: Oral Antibiotic Compliance for ABSSSI

EP. 6: Treatment of ABSSSI: Inpatient Versus Outpatient

EP. 7: ABSSSI: Outpatient Parenteral Antibiotic Therapy

EP. 8: Determining the Severity of ABSSSI

EP. 9: Lipoglycopeptide Therapies for Gram-Positive Infections

EP. 10: Gram-Positive ABSSSI: Early Identification and Follow-Up

EP. 11: ABSSSI Case Scenarios for OPAT

EP. 12: Trends of ABSSSI Incidence in the Community

EP. 13: Establishing Real-World Protocols for OPAT

EP. 14: OPAT Protocols: Navigating Challenges

EP. 15: Lipoglycopeptide Antibiotics for ABSSSI: Education

EP. 16: Standard Protocol for the Treatment of ABSSSI

EP. 17: Cost Considerations for the Treatment of ABSSSI

EP. 18: Risk Stratification for ABSSSI

EP. 19: Long-Acting Lipoglycopeptide Antibiotics for ABSSSI

EP. 20: Establishing a Protocol for OPAT

EP. 21: Future of OPAT for ABSSSI

EP. 1: <i>Pseudomonas</i> Infections in the ICU: Who's Susceptible?

EP. 2: <i>Pseudomonas</i> Infections: Matching Causes and Prevention

EP. 3: <i>Pseudomonas</i> Infections in the ICU Versus on the Floor

EP. 4: <i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics

EP. 5: Fighting <i>Pseudomonas</i>: Impact On Patient Prognosis & Approaches to Combat Infection

EP. 6: Classes and Agents Available to Treat <i>Pseudomonas</i> Infections

EP. 7: <i>Pseudomonas</i> Infections Continue to Acquire Resistance, Complicating Treatment

EP. 8: Exploring Cephalosporin/β-Lactamase Inhibitor Combinations for Treatment of <i>Pseudomonas</i>

EP. 9: Exploring Appropriate Treatment Protocols for <i>Pseudomonas</i> Infections

EP. 10: Core Challenges in <i>Pseudomonas</i> Treatment Protocol

EP. 11: <i>Pseudomonas</i> Infections: Optimizing Diagnostic Strategies

EP. 12: Pseudomonas Infections: Selecting Upfront Antibiotics

EP. 13: <i>Pseudomonas</i> Infections: Secondary Approach to Treatment

EP. 14: Treating <i>Pseudomonas</i> Infections With Zerbaxa or Avycaz

EP. 15: Zerbaxa and Avycaz: Considerations for Treatment

EP. 16: The Future Treatment of Pseudomonas Infections

EP. 1: An Overview of Multidrug-Resistant Bacterial Infections

EP. 2: Understanding the Causes and Impact of MDR Infections

EP. 3: MDR Infections: Current Pathogen and Treatment Paradigm

EP. 4: Gram-Negative Nosocomial Infections: Systemic Risk

EP. 5: Factors in Choosing Therapy for Gram-Negative NIs

EP. 6: Diagnostic Tests for Gram-Negative Nosocomial Infections

EP. 7: Gram-Negative NIs: Vabomere and the TANGO II Study

EP. 8: Gram-Negative NIs: Cephalosporin/β-Lactamase Inhibitors

EP. 9: Understanding Gram-Positive Nosocomial Infections

EP. 10: Selecting Lipoglycopeptide Therapy for Gram-Positive NIs

EP. 11: Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy

EP. 12: Gram-Positive NIs: Costs of Lipoglycopeptide Therapy

EP. 13: MDR Infections: Overview of Antimicrobial Stewardships

EP. 14: Importance of Technology & Data Within Antibiotic Stewardship Programs

EP. 15: Antimicrobial Stewardship Programs: Goals and Challenges

EP. 16: Multidrug-Resistant Bacterial Infections: Key Messages